Dechra Pharmaceuticals PLC Directorate Change (9129U)
03 April 2019 - 5:01PM
UK Regulatory
TIDMDPH
RNS Number : 9129U
Dechra Pharmaceuticals PLC
03 April 2019
The information contained within this announcement contains
inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014. Upon the publication of this announcement via
the Regulatory Information Service, this inside information is now
considered to be in the public domain.
Wednesday, 3 April 2019
Dechra(R) Pharmaceuticals PLC
("Dechra" or "the Company")
Directorate Change
Dechra announces that Richard Cotton, the Company's Chief
Financial Officer, has informed the Board of his decision to leave
the Company immediately for personal reasons.
The Board has agreed that with immediate effect Richard will
resign as Director and relinquish his current responsibilities but
remain available to the Group until 28 June 2019. The Company would
like to thank Richard for his contribution during his service and
wish him well for the future.
The search process for a replacement has commenced and a further
update on this will be made in due course. In the interim period,
Paul Sandland, DVP EU Finance Director, will assume the role of
Acting Chief Financial Officer until a permanent successor to
Richard is appointed.
Trading across the Group has continued to witness growth and is
in line with management expectations as we stated in the Half Year
results released last month.
The Company expects to release its next Trading update in July,
ahead of its Annual results scheduled for publication in
September.
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606
814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785
e-mail: fiona@tooleystreet.com 703 523
Office: +44 (0) 121
309 0099
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Its expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALFFLISRIFIIA
(END) Dow Jones Newswires
April 03, 2019 02:01 ET (06:01 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024